Zydus receives USFDA's nod for Mycophenolate Mofetil for Injection USP

02 Sep 2017 Evaluate

Zydus Cadila has received the final approval from the USFDA to market Mycophenolate Mofetil for Injection USP, 500 mg/vial. The drug is indicated for use in combination with other drugs i.e., cyclosporine and corticosteroids for the prophylaxis of organ rejection in patients receiving renal, hepatic or cardiac transplants.

The drug will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad. The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

922.05 0.80 (0.09%)
16-Dec-2025 11:46 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1788.20
Dr. Reddys Lab 1275.00
Cipla 1506.60
Zydus Lifesciences 922.05
Lupin 2091.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×